Show simple item record

Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial

dc.contributor.authorPorter, Den_US
dc.contributor.authorvan Melckebeke, Jen_US
dc.contributor.authorDale, Jen_US
dc.contributor.authorMessow, CMen_US
dc.contributor.authorMcConnachie, Aen_US
dc.contributor.authorWalker, Aen_US
dc.contributor.authorMunro, Ren_US
dc.contributor.authorMcLaren, Jen_US
dc.contributor.authorMcRorie, Een_US
dc.contributor.authorPackham, Jen_US
dc.contributor.authorBuckley, CDen_US
dc.contributor.authorHarvie, Jen_US
dc.contributor.authorTaylor, Pen_US
dc.contributor.authorChoy, Een_US
dc.contributor.authorPitzalis, Cen_US
dc.contributor.authorMcInnes, IBen_US
dc.date.accessioned2019-07-04T07:49:00Z
dc.date.available2016-05-15en_US
dc.date.issued2016-07-16en_US
dc.identifier.issn0140-6736en_US
dc.identifier.urihttps://qmro.qmul.ac.uk/xmlui/handle/123456789/58356
dc.format.extent239 - 247en_US
dc.relation.ispartofLANCETen_US
dc.titleTumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trialen_US
dc.typeArticle
dc.rights.holder© 2016 Elsevier Ltd. All rights reserved.
dc.identifier.doi10.1016/S0140-6736(16)00380-9en_US
pubs.author-urlhttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000379736100027&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6aen_US
pubs.issue10041en_US
pubs.notesNot knownen_US
pubs.publication-statusPublisheden_US
pubs.volume388en_US
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record